Highlights Cereno Scientific AB

Equities

CRNO B

SE0008241558

Market Closed - Nasdaq Stockholm Other stock markets 11:29:44 2024-05-13 am EDT			5-day change	1st Jan Change
3.794 ^SEK	-2.67%		+0.21%	-17.07%

May. 02	Cereno Scientific AB Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025	CI
Apr. 16	Cereno Scientific AB Approves Election of New Directors	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate	Apr. 11	MT
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment	Apr. 10	MT
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014	Apr. 10	CI
Cereno Scientific Receives Patent Expansion in Europe	Apr. 09	MT
Cereno Scientific Obtains New European Patent for Hypertension Drug Candidate	Mar. 22	MT
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH	Mar. 21	CI
Cereno Scientific Appoints Don De Bethizy as Board of Directors	Mar. 14	CI
Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH	Mar. 06	CI
Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH	Feb. 29	CI
Cereno Scientific AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH	Feb. 21	CI
Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension	Jan. 31	CI
Cereno Scientific Pens Contact with CordenPharma for Scaled Manufacturing of Hypertension Drug	Jan. 11	MT
Cereno Scientific Submits Request to the FDA for "Compassionate Use" of CS1 for Treatment of Patients with Rare Disease Pulmonary Arterial Hypertension	Jan. 04	CI
Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH	Dec. 21	CI
Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting	Dec. 13	CI
Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585	Dec. 12	CI
Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study	Dec. 01	CI
Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family	Nov. 28	CI
Cereno Scientific AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cereno Scientific AB

Equities

CRNO B

SE0008241558

Highlights

Filters